These companies operated pharmacy wholesaling and retailing in New Zealand, the manufacture of over the counter pharmaceuticals, and wholesale distribution of dental products.

This propelled API to restructure its operations to focus primarily on growing its pharmaceutical distribution, retailing and manufacturing business.

[citation needed] The next year, API continued to narrow its focus to the pharmacy channel and sold the Halas Dental business.

[2] In 2007, API divested its House and Price Attack brands as part of its retail strategy to focus on Priceline.

API chose to write the full amount off their annual profit, causing a net loss of $17.2 million.

The company's CEO Jeff Sher resigned after a strategic difference with the board in relation to the treatment of the accounting discrepancy which was proven to have historical significance predating the API acquisition of Priceline.

[10][11] Rival company Sigma Pharmaceuticals attempted to take over API in 2002, but was blocked by the Australian Competition & Consumer Commission.